Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential Application of Emicizumab and Factor VIII Concentrate for Patients with Hemophilia A
TCTR20230705005Phase 4Unknown
- Sponsor
- Division of Pediatric Hematology
- Start
- Jan 2023
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, single-arm trial of emicizumab and Factor VIII in hemophilia A, sponsored by Division of Pediatric Hematology. Primary endpoint: Annual bleeding rate. Status: unknown.
02
Drugs
emicizumabFactor VIII
03
Conditions
hemophilia A
Beyond the preview
Go deeper on TCTR20230705005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20230705005.